1. Home
  2. DAKT vs JANX Comparison

DAKT vs JANX Comparison

Compare DAKT & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Daktronics Inc.

DAKT

Daktronics Inc.

HOLD

Current Price

$17.98

Market Cap

963.2M

Sector

Industrials

ML Signal

HOLD

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

HOLD

Current Price

$17.47

Market Cap

975.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DAKT
JANX
Founded
1968
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Office Equipment/Supplies/Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
963.2M
975.7M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
DAKT
JANX
Price
$17.98
$17.47
Analyst Decision
Buy
Analyst Count
0
13
Target Price
N/A
$47.00
AVG Volume (30 Days)
720.4K
838.7K
Earning Date
03-04-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
538.10
N/A
EPS
0.40
N/A
Revenue
$608,932,000.00
$10,000,000.00
Revenue This Year
$12.06
N/A
Revenue Next Year
$9.16
N/A
P/E Ratio
$44.15
N/A
Revenue Growth
6.89
N/A
52 Week Low
$17.09
$12.12
52 Week High
$28.27
$35.34

Technical Indicators

Market Signals
Indicator
DAKT
JANX
Relative Strength Index (RSI) 34.92 47.65
Support Level N/A $13.00
Resistance Level $20.80 $19.14
Average True Range (ATR) 0.76 0.75
MACD -0.10 -0.28
Stochastic Oscillator 12.17 26.23

Price Performance

Historical Comparison
DAKT
JANX

About DAKT Daktronics Inc.

Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Share on Social Networks: